Costs and benefits of the MRSA Search and Destroy policy in a Dutch hospital

Article

Abstract

The objective of this study was to determine the costs and benefits of the MRSA Search and Destroy policy in a Dutch hospital during 2001 through 2006. Variable costs included costs for isolation, contact tracing, treatment of carriers and closure of wards. Fixed costs were the costs for the building of isolation rooms and the salary of one full-time infection control practitioner. To determine the benefits of the Search and Destroy policy, the transmission rate during the study period was calculated. Furthermore, the number of cases of meticillin-resistant Staphylococcus aureus (MRSA) bacteraemia prevented was estimated, as well as its associated prevented costs and patient lives. The costs of the MRSA policy were estimated to be €215,559 a year, which equals €5.54 per admission. The daily isolation costs for MRSA-suspected and -positive hospitalised patients were €95.59 and €436.62, respectively. Application of the Search and Destroy policy resulted in a transmission rate of 0.30 and was estimated to prevent 36 cases of MRSA bacteraemia per year, resulting in annual savings of €427,356 for the hospital and ten lives per year (95% confidence interval [CI] 8–14). In conclusion, application of the MRSA Search and Destroy policy in a hospital in a country with a low endemic MRSA incidence saves money and lives.

References

  1. 1.
    Kluytmans-VandenBergh MFQ, Kluytmans JAJW (2006) Community-acquired methicillin-resistant Staphylococcus aureus: current perspectives. Clin Microbiol Infect 12(Suppl 1):9–15PubMedCrossRefGoogle Scholar
  2. 2.
    Tiemersma EW, Monnet DL, Bruinsma N, Skov R, Monen JCM, Grundmann H (2005) Staphylococcus aureus bacteremia, Europe. Emerg Infect Dis 11:1798–1799PubMedGoogle Scholar
  3. 3.
    Dutch Working Party on Infection Prevention (WIP) (2007) MRSA hospital. Available online at: http://www.wip.nl/UK/free_content/Richtlijnen/MRSA%20hospital.pdf
  4. 4.
    van Rijen MML, Van Keulen PH, Kluytmans JAJW (2008) Increase in a Dutch hospital of methicillin-resistant Staphylococcus aureus related to animal farming. Clin Infect Dis 46(2):261–263PubMedCrossRefGoogle Scholar
  5. 5.
    van Loo I, Huijsdens X, Tiemersma E, de Neeling A, van de Sande-Bruinsma N, Beaujean D, Voss A, Kluytmans J (2007) Emergence of methicillin-resistant Staphylococcus aureus of animal origin in humans. Emerg Infect Dis 13:1834–1839PubMedGoogle Scholar
  6. 6.
    Wertheim HF, Ammerlaan HS, Bonten MJ, van den Broek PJ, Troelstra A, Vandenbroucke-Grauls CM, Vos MC, Voss A, Nouwen JL, Kluytmans JA (2008) Optimisation of the antibiotic policy in the Netherlands. XII. The SWAB guideline for antimicrobial eradication of MRSA in carriers. Ned Tijdschr Geneeskd 152(49):2667–2671PubMedGoogle Scholar
  7. 7.
    Vriens M, Blok H, Fluit A, Troelstra A, van der Werken C, Verhoef J (2002) Costs associated with a strict policy to eradicate methicillin-resistant Staphylococcus aureus in a Dutch university medical center: a 10-year survey. Eur J Clin Microbiol Infect Dis 21:782–786PubMedCrossRefGoogle Scholar
  8. 8.
    Nulens E, Broex E, Ament A, Deurenberg RH, Smeets E, Scheres J, van Tiel FH, Gordts B, Stobberingh EE (2008) Cost of the meticillin-resistant Staphylococcus aureus search and destroy policy in a Dutch university hospital. J Hosp Infect 68(4):301–307PubMedCrossRefGoogle Scholar
  9. 9.
    Griffiths C, Lamagni TL, Crowcroft NS, Duckworth G, Rooney C (2004) Trends in MRSA in England and Wales: analysis of morbidity and mortality data for 1993–2002. Health Stat Q 21:15–22PubMedGoogle Scholar
  10. 10.
    Wyllie DH, Crook DW, Peto TEA (2006) Mortality after Staphylococcus aureus bacteraemia in two hospitals in Oxfordshire, 1997–2003: cohort study. BMJ 333(7562):281PubMedCrossRefGoogle Scholar
  11. 11.
    Cosgrove SE, Qi Y, Kaye KS, Harbarth S, Karchmer AW, Carmeli Y (2005) The impact of methicillin resistance in Staphylococcus aureus bacteremia on patient outcomes: mortality, length of stay, and hospital charges. Infect Control Hosp Epidemiol 26(2):166–174PubMedCrossRefGoogle Scholar
  12. 12.
    Bootsma MC, Diekmann O, Bonten MJ (2006) Controlling methicillin-resistant Staphylococcus aureus: quantifying the effects of interventions and rapid diagnostic testing. Proc Natl Acad Sci USA 103(14):5620–5625PubMedCrossRefGoogle Scholar
  13. 13.
    Cosgrove SE, Sakoulas G, Perencevich EN, Schwaber MJ, Karchmer AW, Carmeli Y (2003) Comparison of mortality associated with methicillin-resistant and methicillin-susceptible Staphylococcus aureus bacteremia: a meta-analysis. Clin Infect Dis 36:53–59PubMedCrossRefGoogle Scholar
  14. 14.
    Klevens RM, Morrison MA, Nadle J, Petit S, Gershman K, Ray S, Harrison LH, Lynfield R, Dumyati G, Townes JM, Craig AS, Zell ER, Fosheim GE, McDougal LK, Carey RB, Fridkin SK; Active Bacterial Core surveillance (ABCs) MRSA Investigators (2007) Invasive methicillin-resistant Staphylococcus aureus infections in the United States. JAMA 298(15):1763–1771PubMedCrossRefGoogle Scholar

Copyright information

© Springer-Verlag 2009

Authors and Affiliations

  • M. M. L. van Rijen
    • 1
  • J. A. J. W. Kluytmans
    • 2
    • 3
  1. 1.Laboratory for Microbiology and Infection ControlAmphia Hospital BredaBredaThe Netherlands
  2. 2.Laboratory for Microbiology and Infection ControlAmphia Hospital BredaBredaThe Netherlands
  3. 3.Department of Medical Microbiology and Infection ControlVU Medical CentreAmsterdamThe Netherlands

Personalised recommendations